News of Note—Zynerba repeat failure, Fortress spinoff, CEL-SCI lift and more

> A week after Zynerba saw its cannabinoid treatment miss all of its endpoints in epilepsy, it has followed up with a flop in a phase 2 for osteoarthritis with knee pain. “The study did not meet its primary endpoint of reduction from baseline in the weekly mean of the 24-hour average worst pain score at week 12,” the company said, but added there were some glimmers from a “number of secondary endpoints.” Release.

> Fortress Biotech has formed a subsidiary company, Aevitas Therapeutics, to work on new gene therapy approaches for complement-mediated diseases. Its technology, licensed from a “leading university,” could be used toward atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. Statement.

> After nearly a year, the FDA has told microcap CEL-SCI that the clinical hold on its phase 3 cancer test with Multikine (leukocyte interleukin) has been removed, and that all clinical trials with the medication under the IND can now fully restart. Release.


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

> Peregrine will swing the ax on 60 staffers (20% of its workforce) as part of its “series of planned strategic actions to reduce costs and better position the company to achieve overall profitability,” as it also looks out for strategic options for its R&D work. Statement.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.